Compare Iris Energy Limited (IREN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iris Energy Limited vs State Street SPDR S&P Biotech ETF — how do they compare? Iris Energy Limited trades at $35.27 (market cap $14.07B), while State Street SPDR S&P Biotech ETF trades at $153.85 (market cap $10.11B). The key difference: Iris Energy Limited is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Iris Energy Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iris Energy Limited for 28 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| IREN | XBI | |
|---|---|---|
Market Cap | $14.07B | $10.11B |
Volume | 54,492,460 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $76.41 | $169.55 |
52-Week Low | $29.31 | $104.99 |
Typical Hold Time | 28 Days | 38 Days |
Enterprise Value | $16.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IREN shares are trading at $35.19, down 9.05% in the last 24 hours, reflecting ongoing investor concerns despite strong analyst optimism. The stock shows bearish technical signals with key support at $33, while fundamental metrics reveal a challenging profitability picture with a negative net income margin of -99.38% despite revenue growth projections. Recent news highlights the company's aggressive pivot from Bitcoin mining to AI infrastructure, backed by multi-billion dollar contracts with Microsoft and NVIDIA.
The investment case hinges on execution of IREN's ambitious AI infrastructure expansion, with JPMorgan projecting $24 billion in annual revenue by 2030. However, significant risks include ballooning losses, high capital expenditure requirements, and intense competition in the neocloud space. Despite 80% analyst buy ratings and an $81 consensus price target suggesting 130% upside, the stock faces near-term pressure from missed earnings and negative cash flow trends.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iris Energy Limited
Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
